Glycopyrronium Morningside (Glycopyrronium Bromide)

Glycopyrronium Morningside is prescribed for conditions that benefit from reduced cholinergic stimulation. It is commonly used in the following situations:

• Management of excessive salivation (sialorrhea) associated with neurological disorders.
• Adjunct therapy for peptic ulcer disease to decrease gastric secretions.
• Treatment of primary hyperhidrosis (excessive sweating) of the palms, soles, or axillae.
• Off‑label use for reducing drooling in patients with cerebral palsy or after head‑and‑neck surgery.
• Symptomatic relief of gastro‑intestinal spasms in certain functional disorders.

Side effects of glycopyrronium bromide vary in frequency and severity.

Common

• Dry mouth
• Constipation
• Blurred vision
• Urinary retention
• Dizziness or light‑headedness
• Increased heart rate (tachycardia)

Serious

• Severe allergic reactions (rash, swelling, difficulty breathing)
• Acute angle‑closure glaucoma
• Marked tachyarrhythmias
• Persistent urinary retention requiring catheterization
• Severe constipation leading to bowel obstruction

Before starting Glycopyrronium Morningside, consider the following precautions:

• Assess for a history of glaucoma, especially narrow‑angle type.
• Evaluate urinary tract function; avoid use in patients with severe urinary retention.
• Monitor cardiovascular status in patients with tachyarrhythmias or uncontrolled hypertension.
• Use cautiously in the elderly, who may be more susceptible to anticholinergic side effects.
• Discuss pregnancy and breastfeeding status with a healthcare professional, as safety data are limited.
• Adjust dose or discontinue if severe constipation or dry mouth interferes with daily activities.

Glycopyrronium bromide may interact with several drug classes.

Avoid

• Other anticholinergic agents (e.g., antihistamines, tricyclic antidepressants) that may increase anticholinergic burden.
• Medications that prolong the QT interval, as additive cardiac effects are possible.

Use with caution

• Beta‑blockers, which may mask tachycardia.
• Opioids, as combined use can exacerbate constipation.
• Drugs affecting hepatic metabolism (e.g., CYP3A4 inhibitors) that could alter plasma levels.
• Diuretics, due to potential for increased dehydration from dry mouth.